Participants intending to join the question-and-answer segment must register through the company's designated portal, while a general webcast will be accessible to the public. Management suggests logging in at least 15 minutes before the broadcast begins. A full replay of the discussion will be posted to the firm's investor relations page approximately two hours after the live event concludes.
In section Releases
REGENXBIO Schedules Second Quarter 2026 Earnings Call
Investors and analysts will convene on August 6 at 8:00 a.m. ET as Rockville-based REGENXBIO prepares to disclose its financial performance for the second quarter ending June 30. The session serves as a platform to review the company’s current operational progress within its late-stage gene therapy pipeline.
REGENXBIO continues to focus on its AAV gene therapy platform, which currently supports a portfolio of late-stage trials. Key projects include RGX-202 for Duchenne muscular dystrophy, the AbbVie-partnered ABBV-RGX-314 for retinal conditions, and the Nippon Shinyaku-partnered treatments for MPS I and MPS II. The company’s technology also underpins ZOLGENSMA, a treatment marketed by Novartis.
Comments (0)
No comments yet. Be the first!